DMD Digital Health Connections Group Inc - Asset Resilience Ratio
DMD Digital Health Connections Group Inc (APTOF) has an Asset Resilience Ratio of 15.49% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2023)
This chart shows how DMD Digital Health Connections Group Inc's Asset Resilience Ratio has changed over time. Check APTOF PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down DMD Digital Health Connections Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see APTOF company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.98 Million | 15.49% |
| Total Liquid Assets | $1.98 Million | 15.49% |
Asset Resilience Insights
- Good Liquidity Position: DMD Digital Health Connections Group Inc maintains a healthy 15.49% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
DMD Digital Health Connections Group Inc Industry Peers by Asset Resilience Ratio
Compare DMD Digital Health Connections Group Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for DMD Digital Health Connections Group Inc (2014–2023)
The table below shows the annual Asset Resilience Ratio data for DMD Digital Health Connections Group Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $12.99 Million | -- |
| 2022-12-31 | 19.58% | $9.99 Million | $51.03 Million | -28.91pp |
| 2021-12-31 | 48.49% | $40.01 Million | $82.53 Million | +23.99pp |
| 2017-12-31 | 24.49% | $8.60 Million | $35.11 Million | +6.96pp |
| 2016-12-31 | 17.53% | $5.76 Million | $32.87 Million | +12.17pp |
| 2015-12-31 | 5.36% | $1.42 Million | $26.56 Million | +5.20pp |
| 2014-12-31 | 0.16% | $28.00K | $17.92 Million | -- |
About DMD Digital Health Connections Group Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more